P-MTAB-33066 - P-MTAB-33066
Xenografts were treated with either saline vehicle control or a combination of vincristine (VCR; 0.5 mg/kg; Pfizer Australia, West Ryde, Old Toongabbie, NSW, Australia) and daunorubicin (DNR; 2.5mg/kg intravenously; Baxter, NSW, Australia) every 7 days for 4 weeks; both dexamethasone (DEX: 15mg/kg; Sigma-Aldrich, Castle Hill, NSW, Australia) and L-asparaginase (L-ASP: 1000 U/kg; Aventis, Lane Cove, NSW, Australia) were administered five times a week for 4 weeks. The combination of these four drugs (VXLD) was administered on the same schedule at reduced doses for VCR (0.15 mg/kg) and DEX (5mg/kg). As a further improvement to this model we refined a protocol involving an additional round of VXL treatment for 2 weeks(VXLD2). Engraftment and disease progression was monitored by flow cytometric enumeration of the proportion of human versus mouse CD45+ (%huCD45+) cells in peripheral blood using established procedures [Lock et al. 2002]. When the %huCD45+ reached over 50%, animals were culled and tissue was harvested and cryopreserved.